RecruitingPhase 1NCT06751238
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Studying Psoriasis-related juvenile idiopathic arthritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Intervention
- Secukinumab(biological)
- Enrollment
- 20 enrolled
- Eligibility
- 2-17 years · All sexes
- Timeline
- 2025 – 2032
Study locations (7)
- University of Florida, Gainesville, Florida, United States
- Ann and Robert H Lurie Childs Hosp, Chicago, Illinois, United States
- Levine Childrens Hospital, Charlotte, North Carolina, United States
- Cincinnati Childrens Hospital, Cincinnati, Ohio, United States
- Univ Hosp Cleveland Medical Center, Cleveland, Ohio, United States
- Legacy Emanuel Research Hosp Portland, Portland, Oregon, United States
- Texas Arthritis Center, El Paso, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06751238 on ClinicalTrials.govOther trials for Psoriasis-related juvenile idiopathic arthritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06869551A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic ArthritisBristol-Myers Squibb
- RECRUITINGPHASE3NCT06668181An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic ArthritisUCB Biopharma SRL
- RECRUITINGPHASE3NCT06100744A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabAbbVie
- RECRUITINGPHASE3NCT05767047A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic ArthritisAmgen
- ACTIVE NOT RECRUITINGPHASE3NCT05083182A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic ArthritisJanssen Research & Development, LLC
- RECRUITINGPHASE3NCT04804553Apremilast Pediatric Study in Children With Active Juvenile Psoriatic ArthritisAmgen
- ACTIVE NOT RECRUITINGPHASE3NCT04527380A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic ArthritisEli Lilly and Company
See all trials for Psoriasis-related juvenile idiopathic arthritis →